News

Kelly Anspaugh received both a heart and kidney transplant at Saint Luke's.

Adults with obesity-related heart failure and diabetes saw improvements in heart failure symptoms and physical function with semaglutide 2.4 mg compared with placebo, a recent study showed.

Dr. Matthew Wilkinson, a transplant surgeon at Saint Luke’s talks about the advances in organ donation and the importance of living organ donation.

AARP talked to Dr. James O'Keefe about different types of exercise that can help improve longevity.

For people struggling with both diabetes and a common type of heart failure, the weight-loss drug Wegovy may do more for their health than help them shed pounds, new research suggests.

Before his heart transplant, Robert Johnson had a hard time even cutting his grass. Now, after receiving a heart transplant at Saint Luke's Mid America Heart Institute, he is back to enjoying physical activities, like golf.

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.

Saint Luke’s Mid America Heart Institute today announced results from the STEP HFpEF DM trial.